Actively Recruiting
68Ga-RM26-RGD PET/CT Imaging for Breast, Brain, and Prostate Cancers Expressing GRPR and αvβ3 Receptors
Led by Peking Union Medical College Hospital · Updated on 2024-07-05
90
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new dual-target imaging agent called 68Ga-RM26-RGD for PET/CT scans in patients with breast, brain, and prostate cancers that express specific receptors (GRPR and integrin αvβ3). This study aims to improve tumor detection by comparing this agent with conventional 18F-FDG and single-target imaging agents, addressing limitations of current imaging methods in detecting tumors with low 18F-FDG uptake or variable receptor expression. Participants will undergo PET/CT scans using intravenous injections of 68Ga-RM26-RGD and one of the comparator agents (18F-FDG, 68Ga-RM26, or 68Ga-RGD) within a two-week period. The dosages for these agents are approximately 1.8-2.2 MBq/kg. Each patient receives scans with both agents to compare imaging performance directly. During the study, researchers will assess diagnostic accuracy and dosimetry of 68Ga-RM26-RGD over about one year. Participants will have multiple PET/CT scans and related evaluations to monitor uptake of the imaging agents in tumors. The study includes safety and diagnostic performance monitoring throughout the participation period.
CONDITIONS
Brief Title
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected breast, brain, or prostate cancer
- Undergoing 68Ga-RM26-RGD and 18F-FDG (or 68Ga-RM26 or 68Ga-RGD) PET/CT scans within 2 weeks
- Signed written informed consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Any medical condition that may significantly affect study compliance in the investigator's opinion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 2 weeks
Participants undergo PET/CT scans using different imaging agents including 68Ga-RM26-RGD and either 18F-FDG, 68Ga-RM26, or 68Ga-RGD to assess tumor receptor expression and assist diagnosis.
2 visits (in-person) within 2 weeks
Duration - Up to 1 year
Participants are followed for diagnostic performance and dosimetry assessments of the imaging agents.
Visit frequency varies; assessments occur through study completion
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD,PHD
Z
Zhaohui Zhu, MD,PHD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here